Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMLX NASDAQ:PBYI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMLXAmylyx Pharmaceuticals$13.58$15.18$4.64▼$18.60$1.51B-0.111.15 million shs818,486 shsPBYIPuma Biotechnology$7.08$6.95$3.03▼$7.90$360.37M1.24286,622 shs187,001 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMLXAmylyx Pharmaceuticals0.00%+2.26%-20.31%-2.30%+155.74%PBYIPuma Biotechnology0.00%+2.31%-6.10%-0.42%+119.20%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMLXAmylyx Pharmaceuticals$13.58$15.18$4.64▼$18.60$1.51B-0.111.15 million shs818,486 shsPBYIPuma Biotechnology$7.08$6.95$3.03▼$7.90$360.37M1.24286,622 shs187,001 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMLXAmylyx Pharmaceuticals0.00%+2.26%-20.31%-2.30%+155.74%PBYIPuma Biotechnology0.00%+2.31%-6.10%-0.42%+119.20%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMLXAmylyx Pharmaceuticals 2.77Moderate Buy$23.0069.37% UpsidePBYIPuma Biotechnology 2.00HoldN/AN/ACurrent Analyst Ratings BreakdownLatest AMLX and PBYI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/11/2026PBYIPuma Biotechnology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C+) ➝ Hold (C)5/8/2026AMLXAmylyx Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/28/2026AMLXAmylyx Pharmaceuticals MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$19.00 ➝ $21.004/21/2026PBYIPuma Biotechnology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C+)3/25/2026AMLXAmylyx Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$34.003/19/2026AMLXAmylyx Pharmaceuticals GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$25.00 ➝ $30.003/4/2026AMLXAmylyx Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$28.00 ➝ $34.003/3/2026AMLXAmylyx Pharmaceuticals Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$21.00(Data available from 5/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMLXAmylyx PharmaceuticalsN/AN/AN/AN/A$2.46 per shareN/APBYIPuma Biotechnology$228.40M1.58$0.83 per share8.49$2.52 per share2.81Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMLXAmylyx Pharmaceuticals-$144.74M-$1.50N/AN/AN/AN/A-55.69%-50.73%8/6/2026 (Estimated)PBYIPuma Biotechnology$31.11M$0.4814.7537.26N/A10.69%20.30%12.05%8/6/2026 (Estimated)Latest AMLX and PBYI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026AMLXAmylyx Pharmaceuticals-$0.34-$0.37-$0.03-$0.37N/AN/A5/7/2026Q1 2026PBYIPuma Biotechnology-$0.13-$0.04+$0.09-$0.07$42.00 million$44.81 million3/3/2026Q4 2025AMLXAmylyx Pharmaceuticals-$0.31-$0.30+$0.01-$0.30($0.05) millionN/A2/26/2026Q4 2025PBYIPuma Biotechnology$0.24$0.26+$0.02$0.26$68.60 million$75.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAMLXAmylyx Pharmaceuticals$1.027.48%N/AN/A N/APBYIPuma BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMLXAmylyx PharmaceuticalsN/A17.8517.85PBYIPuma BiotechnologyN/A2.382.24Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMLXAmylyx Pharmaceuticals95.84%PBYIPuma Biotechnology61.29%Insider OwnershipCompanyInsider OwnershipAMLXAmylyx Pharmaceuticals12.30%PBYIPuma Biotechnology22.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMLXAmylyx Pharmaceuticals200111.19 million97.51 millionOptionablePBYIPuma Biotechnology20050.90 million39.60 millionOptionableAMLX and PBYI HeadlinesRecent News About These CompaniesPuma Biotechnology Reveal Hidden Strength Amid Rising Market FocusMay 17, 2026 | kalkinemedia.comKWall Street Zen Downgrades Puma Biotechnology (NASDAQ:PBYI) to BuyMay 16, 2026 | americanbankingnews.comPuma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft EarningsMay 14, 2026 | finance.yahoo.comEarnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00May 11, 2026 | finance.yahoo.comPuma Biotechnology (NASDAQ:PBYI) Issues Earnings ResultsMay 9, 2026 | marketbeat.comPuma Biotechnology Q1 Earnings Call HighlightsMay 8, 2026 | marketbeat.comPBYI Q1 Earnings & Sales Beat Estimates, 2026 Guidance RaisedMay 8, 2026 | zacks.comPuma Biotechnology, Inc. (PBYI) Q1 2026 Earnings Call TranscriptMay 8, 2026 | seekingalpha.comPuma Biotech: Q1 Earnings SnapshotMay 8, 2026 | sfgate.comPuma Biotech (PBYI) Reports Q1 Loss, Tops Revenue EstimatesMay 7, 2026 | zacks.comPuma Biotechnology Reports First Quarter 2026 Financial ResultsMay 7, 2026 | businesswire.comUniversal Beteiligungs und Servicegesellschaft mbH Sells 159,200 Shares of Puma Biotechnology, Inc. $PBYIMay 7, 2026 | marketbeat.comPuma Biotechnology (PBYI) to Release Quarterly Earnings on ThursdayApril 30, 2026 | marketbeat.comPuma Biotechnology (NASDAQ:PBYI) Stock Passes Above 200-Day Moving Average - Should You Sell?April 29, 2026 | marketbeat.comPuma Biotechnology to Host Conference Call to Discuss First Quarter 2026 Financial ResultsApril 23, 2026 | finance.yahoo.comPuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)April 2, 2026 | businesswire.comPuma Biotechnology Stock Declines More Than 9% in a Month: Here's WhyMarch 18, 2026 | zacks.comIRWD vs. PBYI: Which Small-Cap Biotech Stock Is a Better Buy?March 12, 2026 | zacks.comPBYI Q4 Earnings & Sales Beat Estimates, Stock Down on Weak 2026 ViewFebruary 27, 2026 | zacks.comPuma Biotechnology Inc (PBYI) Q4 2025 Earnings Call Highlights: Revenue Growth and Strategic ...February 27, 2026 | finance.yahoo.comPuma anticipates $194M–$198M NERLYNX revenue for 2026 while advancing alisertib clinical programsFebruary 26, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 2026Apple Talks Just Changed Everything for IntelBy Sam Quirke | May 6, 20263 Energy Stocks to Buy and 2 to Avoid as AI Power Demand ExplodesBy Bridget Bennett | May 4, 2026Alphabet’s Earnings Didn’t Just Beat—They Changed the StoryBy Ryan Hasson | April 30, 2026Amylyx Stock: Why the Full Pipeline Story MattersBy Chris Markoch | May 24, 2026AMLX and PBYI Company DescriptionsAmylyx Pharmaceuticals NASDAQ:AMLX$13.58 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$13.49 -0.09 (-0.66%) As of 05/22/2026 06:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.Puma Biotechnology NASDAQ:PBYI$7.08 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$7.08 0.00 (-0.07%) As of 05/22/2026 06:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Palantir and Dell Build an AI OS for the Paranoid Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
